title: A soluble ectodomain of LRIG1 inhibits cancer cell growth by attenuating basal and ligand-dependent EGFR activity.
abstract: Leucine-rich repeats and immunoglobulin-like domains-1 (LRIG1) is a transmembrane protein with an ectodomain containing 15 leucine-rich repeats (LRRs) homologous to mammalian decorin and the Drosophila kekkon1 gene. In this study, we demonstrate that a soluble ectodomain of LRIG1, containing only the LRRs, inhibits ligand-independent epidermal growth factor receptor (EGFR) activation and causes growth inhibition of A431, HeLa and MDA-468 carcinoma cells. In contrast, cells that do not express detectable levels of EGFR fail to respond to soluble LRIG1. However, when a functional EGFR gene is introduced in these cells, they become growth-inhibited by soluble LRIG1 protein. Furthermore, we demonstrate the existence of high-affinity (K(d)=10 nM) binding sites on the A431 cells that can be competitively displaced (up to 75%) by molar excess of EGF. Even more powerful effects are obtained with a chimeric proteoglycan harboring the N-terminus of decorin, substituted with a single glycosaminoglycan chain, fused to the LRIG1 ectodomain. Both proteins also inhibit ligand-dependent activation of the EGFR and extracellular signal-regulated protein kinase 1/2 signaling in a rapid and dose-dependent manner. These results suggest a novel mechanism of action evoked by a soluble ectodomain of LRIG1 protein that could modulate EGFR signaling and its growth-promoting activity. Attenuation of EGFR activity without physical downregulation of the receptor could represent a novel therapeutic approach toward malignancies in which EGFR plays a primary role in tumor growth and survival.
authors.affiliation: Department of Pathology, Anatomy and Cell Biology, Thomas Jefferson University, Philadelphia, PA 19107, USA.
authors.forename: S
authors.initials: S
authors.lastname: Goldoni
authors.forename: R A
authors.initials: RA
authors.lastname: Iozzo
authors.forename: P
authors.initials: P
authors.lastname: Kay
authors.forename: S
authors.initials: S
authors.lastname: Campbell
authors.forename: A
authors.initials: A
authors.lastname: McQuillan
authors.forename: C
authors.initials: C
authors.lastname: Agnew
authors.forename: J-X
authors.initials: JX
authors.lastname: Zhu
authors.forename: D R
authors.initials: DR
authors.lastname: Keene
authors.forename: C C
authors.initials: CC
authors.lastname: Reed
authors.forename: R V
authors.initials: RV
authors.lastname: Iozzo
mesh_terms: D000595:Amino Acid Sequence; D000818:Animals; D001665:Binding Sites; D016466:CHO Cells; D049109:Cell Proliferation; D006224:Cricetinae; D003412:Cricetulus; D058575:Decorin; D066246:ErbB Receptors / Q000378:metabolism*; D016326:Extracellular Matrix Proteins / Q000235:genetics / Q000378:metabolism; D005786:Gene Expression Regulation / Q000502:physiology*; D005799:Genes, Dominant; D006367:HeLa Cells; D006801:Humans; D008024:Ligands; D008562:Membrane Glycoproteins / Q000235:genetics*; D008969:Molecular Sequence Data; D011485:Protein Binding; D011509:Proteoglycans / Q000235:genetics / Q000378:metabolism; D011994:Recombinant Proteins / Q000235:genetics / Q000302:isolation & purification / Q000378:metabolism; D017386:Sequence Homology, Amino Acid; D015398:Signal Transduction; D014407:Tumor Cells, Cultured / Q000378:metabolism / Q000473:pathology
chemical_list: C546878:DCN protein, human; D058575:Decorin; D016326:Extracellular Matrix Proteins; C484445:LRIG1 protein, human; D008024:Ligands; D008562:Membrane Glycoproteins; D011509:Proteoglycans; D011994:Recombinant Proteins; D066246:ErbB Receptors